The Week in Review: April 13 – April 20, 2018

Friday, April 20, 2018 News Recap: Green tea supplements may cause liver damage, warns EU watchdog. Green tea extracts may cause liver damage, the EU food safety watchdog today announced. Taking more than 800mg of green tea catechins each day may pose health concerns, according to the body's review. Officials were unable to confirm a safe dose. Race May Affect Ability to Achieve SVR in Hepatitis C.  After being treated with direct-acting antiviral...

Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure

A large-scale study evaluating the feasibility of decentralized care and the provision of free direct-acting antiviral agents (DAAs) has reported high rates of cure among a population of almost 20,000 individuals completing treatment for hepatitis C virus (HCV) infection. The study conducted in Punjab, India, which was reported today at The International Liver Congress™ 2018 in Paris, France, validated the efficacy and safety of generic all-oral DA

The Week in Review: March 23 – April 6, 2018

Friday, April 6, 2018 News Recap: HCV – Liver Cancer (HCC): Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. Testing for he...

Hepatitis: India to keep fighting, new test may come handy

According to experts, with challenges such as awareness, accessibility, compliance and affordability, India can only eradicate hepatitis by 2080 (as against global goal of 2030) if they start acting now. In 2016, of the 400 million people infected by viral hepatitis globally, about 13% were Indians. "There is need for immediate and urgent action to arrest the spread of hepatitis. In the South-East Asia Region, viral hepatitis is driving rates of liver can

Hepatitis C drugs re-energize global fight over patents

Lawsuits in India and Argentina seek to reduce drug costs by allowing generic versions of antiviral treatments. The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries. In the 2000s,

Hepatitis C Patent Challenges In India, Argentina To Allow Generic Production

Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals). According to a Médecins Sans Frontières (MSF, Doctors Without Borders) press release, on 13 February the Initiative for Medicines, Access & Kn

All You Need to Know: September’s Crucial Verdict on the Sofosbuvir Patent Saga

The patent also covers the raw materials to make the drugs, which means it would allow the manufacturer to disrupt exports of the raw materials from India. In September, India will witness the first hearing in a crucial court case on the grant of a patent for the anti-hepatitis-C drug sofosbuvir – a drug whose patent was rejected and then approved by the same patent court, albeit by two different officials. A recent report of the international medical cha

India may soon get Epclusa treatment for Hepatitis C

WASHINGTON: A latest breakthrough treatment for the deadly Hepatitis C virus could soon be available in India as 11 Indian firms have been given licenses by its American manufacturer following an approval from US authorities. The drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences in its latest breakthrough treatment was last week approved by the US Food and Drug Administration (FDA). The deadly Hep

India: Punjab: Government launches special fund for free treatment of Hepatitis C

Punjab becomes the first state in India to provide free treatment to patients diagnosed with Hepatitis C Punjab Chief Minister Parkash Singh Badal has launched a special fund called ‘Mukh Mantri Punjab Hepatitis C Relief Fund’ to provide free treatment for patients affected by Hepatitis C. With this initiative, Punjab has become the first state in the country to provide free treatment to confirmed cases of Hepatitis C, a spokesperson claimed. Punjab

Update: India Patent Office approves Gilead’s hepatitis C drug patent

India has reversed course and granted approval to Gilead Sciences Inc's (GILD.O) patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable copies of the drug. The drug, which has a list price of $1,000 a pill in the United States, was rejected for a patent by the Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the company alrea